Market Overview

20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Share:

Gainers

AC Immune, Inc. (NASDAQ:ACIU) shares rose 88.45% to $13.55 during Thursday's pre-market session.

Nabriva Therapeutics, Inc. (NASDAQ:NBRV) stock increased by 62.40% to $1.08.

Lannett, Inc. (NYSE:LCI) shares increased by 28.27% to $6.60.

Tiziana Life Sciences, Inc. (NASDAQ:TLSA) shares rose 10.42% to $9.53.

Intec Pharma, Inc. (NASDAQ:NTEC) shares moved upwards by 9.39% to $0.34.

Veru, Inc. (NASDAQ:VERU) shares increased by 7.66% to $3.37. The most recent rating by Oppenheimer, on May 14, is at Outperform, with a price target of $9.

Adamis Pharmaceuticals, Inc. (NASDAQ:ADMP) shares increased by 6.47% to $0.70. The most recent rating by Maxim Group, on May 13, is at Buy, with a price target of $2.

NextCure, Inc. (NASDAQ:NXTC) shares moved upwards by 5.10% to $9.47. The most recent rating by Benchmark, on Jul 16, is at Buy, with a price target of $17.

Enzo Biochem, Inc. (NYSE:ENZ) shares rose 4.39% to $2.61.

BioNTech, Inc. (NASDAQ:BNTX) stock increased by 3.97% to $81.10. The most recent rating by Canaccord Genuity, on Jul 13, is at Buy, with a price target of $75.

 

Losers

Tricida, Inc. (NASDAQ:TCDA) stock decreased by 33.63% to $17.39 during Thursday's pre-market session.

INmune Bio, Inc. (NASDAQ:INMB) stock fell 16.48% to $10.90. The most recent rating by HC Wainwright & Co., on Jul 15, is at Buy, with a price target of $20.

Lianluo Smart, Inc. (NASDAQ:LLIT) stock decreased by 12.40% to $0.52.

Aptose Biosciences, Inc. (NASDAQ:APTO) stock fell 11.83% to $5.52.

VIVUS, Inc. (NASDAQ:VVUS) stock decreased by 9.31% to $0.47.

Genetic Technologies, Inc. (NASDAQ:GENE) stock decreased by 8.29% to $5.20.

Immutep, Inc. (NASDAQ:IMMP) stock declined 8.22% to $1.34.

Ocugen, Inc. (NASDAQ:OCGN) shares declined 6.63% to $0.20. The most recent rating by Chardan Capital, on Jun 3, is at Buy, with a price target of $1.

Equillium, Inc. (NASDAQ:EQ) shares declined 6.24% to $16.25. The most recent rating by HC Wainwright & Co., on Jul 14, is at Buy, with a price target of $24.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shares declined 5.49% to $3.10. The most recent rating by JP Morgan, on May 27, is at Overweight, with a price target of $6.

 

Related Articles (NBRV + ACIU)

View Comments and Join the Discussion!

Posted-In: Healthcare Stocks Pre-Market MoversPre-Market Outlook Markets Movers Trading Ideas